Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia

被引：3
|
作者：
Al-Samkari, Hanny [1 ,2 ,9 ]
Jiang, Debbie [3 ,4 ]
Gernsheimer, Terry [3 ,4 ]
Liebman, Howard [5 ]
Lee, Susie [5 ]
Bernheisel, Chelsea
Wojdyla, Matthew [6 ]
Vredenburg, Michael [6 ]
Cuker, Adam [7 ,8 ]
机构：
[1] Massachusetts Gen Hosp, Div Hematol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Washington, Div Hematol, Seattle, WA USA
[4] Seattle Canc Care Alliance, Seattle, WA USA
[5] Univ Southern Calif, Keck Sch Med, Hematol, Los Angeles, CA USA
[6] Sobi Inc, Durham, NC USA
[7] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA
[8] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA USA
[9] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
来源：
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS | 2023年 / 7卷 / 03期
关键词：
avatrombopag; eltrombopag; immune thrombocytopenia; romiplostim; thrombopoietin receptor;
D O I：
10.1016/j.rpth.2023.100134
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations
    Aoki, T.
    Harada, Y.
    Matsubara, E.
    Suzuki, T.
    Oyama, T.
    Kasai, M.
    Uchida, T.
    Ogura, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (06) : 729 - 732
  • [22] Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales
    Allen, Rachel
    Bryden, Peter
    Grotzinger, Kelly M.
    Stapelkamp, Ceilidh
    Woods, Bethan
    VALUE IN HEALTH, 2016, 19 (05) : 614 - 622
  • [23] Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Roy, Anuja
    Elliott, Brian
    Briggs, Andrew
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 715 - 721
  • [24] Avatrombopag increased platelet count in a patient with chronic immune thrombocytopenia refractory to multiple lines of treatment
    Lebowa, Weronika
    Zdziarska, Joanna
    Sacha, Tomasz
    BLOOD COAGULATION & FIBRINOLYSIS, 2023, 34 (05) : 327 - 332
  • [25] Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia
    Morales, Luis F.
    Miyara, Santiago J.
    Guevara, Sara
    Metz, Christine N.
    Shoaib, Muhammad
    Watt, Stacey
    Zafeiropoulos, Stefanos
    McCann-Molmenti, Alexia
    Hayashida, Kei
    Takegawa, Ryosuke
    Shinozaki, Koichiro
    Choudhary, Rishabh C.
    Brindley, Elena C.
    Nishikimi, Mitsuaki
    Kressel, Adam M.
    Alsalmay, Yaser M.
    Mazzotta, Elvio A.
    Cho, Young Min
    Aranalde, Gabriel, I
    Grande, Daniel A.
    Zanos, Stavros
    Becker, Lance B.
    Molmenti, Ernesto P.
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2021,
  • [26] Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
    Cai, Xuan
    Fu, Haixia
    Zhao, Xiangyu
    Lu, Jin
    Jiang, Qian
    Chang, Yingjun
    Huang, Xiaojun
    Zhang, Xiaohui
    CHINESE MEDICAL JOURNAL, 2022, 135 (19) : 2344 - 2350
  • [27] Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Elliott, Brian
    Briggs, Andrew
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 705 - 713
  • [28] Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study
    Newland, Adrian
    Godeau, Bertrand
    Priego, Victor
    Viallard, Jean-Francois
    Lopez Fernandez, Maria F.
    Orejudos, Amelia
    Eisen, Melissa
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (02) : 262 - 273
  • [29] In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation
    Psaila, Bethan
    Bussel, James B.
    Linden, Matthew D.
    Babula, Bracken
    Li, Youfu
    Barnard, Marc R.
    Tate, Chinara
    Mathur, Kanika
    Frelinger, Andrew L.
    Michelson, Alan D.
    BLOOD, 2012, 119 (17) : 4066 - 4072
  • [30] Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study
    Cai Xuan
    Fu Haixia
    Zhao Xiangyu
    Lu Jin
    Jiang Qian
    Chang Yingjun
    Huang Xiaojun
    Zhang Xiaohui
    中华医学杂志英文版, 2022, 135 (19)
12345